Multiple pathways and proteins – not individually validated

The term Multiple pathways and proteins – not individually validated is a categorical designation used in pharmacological databases, such as ChEMBL, to describe therapeutic agents that do not interact with a single, well-defined molecular target (Gaulton et al., 2017). This classification is often applied to complex mixtures, natural products, or drugs with broad polypharmacology where the clinical effect is the result of modulating an entire network of biological processes rather than a specific protein or receptor (Mendez et al., 2019). Because the therapeutic driver is not pinpointed to a specific gene product, these agents are characterized by a lack of mechanistic clarity. This absence of a validated target presents significant hurdles for biotech analysts and drug developers, particularly regarding the design of rational lead optimization and the identification of predictive biomarkers for patient stratification. While multi-target strategies can be effective for systemic diseases, they carry an inherent risk of unforeseen off-target interactions and complex safety profiles that are difficult to manage during clinical development. Consequently, this designation reflects a gap in molecular understanding that requires further experimental validation to resolve into specific target-ligand interactions.

Other names

Multi-target mechanismNon-specific pathwaysUnvalidated targetsPolypharmacological mechanismUnspecified target

The mechanism of action involves the simultaneous modulation of multiple biological pathways and proteins that have not been individually isolated or validated as the primary therapeutic target.